-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Elicio Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2020 to Q2 2024.
- Elicio Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$7.23M, a 4.37% increase year-over-year.
- Elicio Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$38.7M, a 31.3% decline year-over-year.
- Elicio Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$35.2M, a 24.8% decline from 2022.
- Elicio Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$28.2M, a 48.3% increase from 2021.
- Elicio Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$54.6M, a 31.9% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)